Horseshoe Crab Welfare in Medical Harvest and Conservation

Horseshoe crabs are harvested for their blue blood used in medical testing — their welfare during bleeding and mortality from this practice raises ethical questions.

Key Facts

• Horseshoe crabs are not true crabs but chelicerates — they are more closely related to spiders
• Limulus amebocyte lysate (LAL) from horseshoe crab blood detects bacterial endotoxins in medical supplies
• An estimated 500,000 horseshoe crabs are bled annually for LAL production in the US
• Mortality from the biomedical bleeding process is estimated at 10-30% of bled animals
• Recombinant factor C (rFC) is an alternative that eliminates the need for horseshoe crab bleeding

Welfare Considerations

Horseshoe crab welfare in biomedical harvest involves capture from beaches, transport to facilities, bleeding of approximately 30% of blood volume, and return to the ocean — a process with documented mortality of 10-30%. The welfare of the bleeding process itself is uncertain — horseshoe crabs have simple immune-based nervous systems, and their capacity for pain experience in the human-like sense is not established. However, the physiological stress of blood removal at this volume is documented. The welfare case for transition to rFC alternative is compelling on both welfare and conservation grounds — rFC eliminates harvest mortality entirely while providing equivalent endotoxin detection. Conservation concerns about declining horseshoe crab populations add urgency to welfare-motivated transition to alternatives.

What You Can Do

• Support the adoption of recombinant Factor C (rFC) as an alternative to horseshoe crab LAL bleeding
• Advocate for medical regulatory acceptance of rFC to remove barriers to adoption
• Support horseshoe crab population monitoring and spawning beach conservation
• Engage pharmaceutical companies about their timeline for transitioning from LAL to rFC
• Support research into horseshoe crab sensory biology to clarify welfare status during bleeding